Wegovy 0.25mg Results: What the Evidence Actually Shows

What the STEP 1 trial tells us about the starter phase

The STEP 1 trial recruited 1,961 adults with obesity and followed them for 68 weeks. Participants were titrated up to 2.4mg semaglutide over approximately 16 weeks before spending the remaining time at the maintenance dose. Average body weight fell by around 15% over the full study period. No sub-analysis was published that isolates results at 0.25mg alone, because the starting dose was not designed to produce a measurable therapeutic effect in its own right. The NHS medicines information for semaglutide confirms this framing: 0.25mg is described explicitly as an initiation dose to improve tolerability, with dose escalation required to reach efficacy.

This distinction matters. Some people come off 0.25mg having lost a small amount of weight (occasionally a few kilograms) and others notice very little change, and our page covering 0.25mg Wegovy results explores what real-world outcomes at this stage tend to look like. Both outcomes are normal at this stage. The medicine's appetite-suppressing effect intensifies as the dose climbs, and the trial's weight-loss figures reflect where patients end up, not where they start.

What you might notice at 0.25mg is a mild reduction in hunger, perhaps some gastrointestinal discomfort in the first week or two, and a gradual sense that large portions feel less comfortable. These are signs the medicine is active. The job of 0.25mg is adjustment, not transformation.

Why the titration schedule is built the way it is

Semaglutide's most common side effects (nausea, loose stools, indigestion, occasional vomiting) are dose-dependent. Starting lower and climbing slowly gives the gut time to adapt. The licensed schedule moves in steps roughly every four weeks: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, then 2.4mg. You can read more about how the doses relate to each other on the Wegovy dosing overview page.

The prescriber, not the patient, decides whether to proceed to the next step or hold at a lower dose for longer. If side effects at 0.25mg are significant, staying there for an additional four weeks before moving up is clinically appropriate and does not affect long-term outcomes. If the step up to 0.5mg is also well tolerated, the journey to maintenance can proceed on schedule. Changing the timing without clinical input is not advised; the Patient Information Leaflet and your prescriber are the right reference points for any adjustments.

One thing patients often find reassuring: slow progress through titration does not predict slower weight loss at maintenance. Tolerability at the lower doses is largely unrelated to eventual response at 2.4mg.

What to track at 0.25mg, and what to set aside for now

The most useful things to notice during the 0.25mg phase are how your body is responding to the medicine, not how much weight you have lost. Mild nausea that fades within a few days is expected. Persistent or severe stomach pain, particularly if it radiates toward your back, warrants medical attention promptly and should not be dismissed as normal adjustment; the MHRA's Yellow Card scheme exists for reporting any suspected side effects, and your prescriber should know about anything that concerns you.

Weight at this stage can fluctuate because of changes in water retention, eating patterns or digestive transit time rather than fat loss. A small number on the scale is not evidence that the medicine is working yet, and a unchanged number is not evidence that it is failing. That context is worth holding onto.

For people curious about how results develop as the dose increases, the 0.5mg results page covers the next step in the schedule, and those moving on to the 1mg stage can find a detailed breakdown on our 1mg Wegovy results page. Evidence from the full titration through to 2.4mg is covered on the 2.4mg results page, which is where the headline trial figures originate. If you are considering whether Wegovy is the right approach for your situation at all, the weight-loss treatment overview sets out the licensed options available through a regulated UK pharmacy.

A consultation with a qualified prescriber is the proper place to discuss your individual progress, eligibility and next steps. If you haven't started treatment yet and want your situation assessed by a clinician, checking your eligibility takes a few minutes and is free.